收藏切换
A new paradigm for novel drug development incorporating Phase 0 clinical trial
收藏切换
PDF
Yan LIN1a, b, Qiao-hui LIANG1c, Zhi-xia JIANG1d, 2, Jing CAI1a, 3, Guang-ji WANG1b, Jin YANG1e
Chinese Journal of Clinical Pharmacology | 2026, 42(4) : 565 - 572
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2026, 42(4): 565-572
Review
A new paradigm for novel drug development incorporating Phase 0 clinical trial
Full
Yan LIN1a, b, Qiao-hui LIANG1c, Zhi-xia JIANG1d, 2, Jing CAI1a, 3, Guang-ji WANG1b, Jin YANG1e
Affiliations
  • 1a.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
  • 1b.State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
  • 1c.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
  • 1d.School of Science, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
  • 1e.School of Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
  • 2.Shanghai Guanhe Pharmaceutical Technology Co., Ltd., Shanghai 200433, China
  • 3.The Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830028, Xinjiang Uyghur Autonomous Region, China
Published: 2026-02-28 doi: 10.13699/j.cnki.1001-6821.2026.04.018
Outline
收藏切换

Novel drug research and development has high failure rate and “a narrow escape from death”, which needs to strike a balance between rapid progress, development risk and cost reduction and scientific decision-making, it is necessary to achieve "two early": eliminate drugs that may fail as early as possible with little investment, obtain key evidence as early as possible to enhance confidence in subsequent research and development, which is also known as "Quick win, fast fail" concept. Phase 0 clinical trial, as an early exploratory research tool, has the characteristics of low dose, short cycle, small number of subjects, and flexible application requirements. It is mainly used to rapidly evaluate the potential of drug candidates for further development, and more efficiently screen and develop potential drug candidates. The Phase 0 clinical trial strategy requires a variety of specific technologies and qualified personnel, including radiopharmaceutical labeling techniques, high-sensitivity analysis techniques, imaging techniques, pharmacokinetic and pharmacodynamic modeling, ethical review and subject recruitment, as well as multidisciplinary team collaboration and highly specialized research institutions. The effective integration and collaboration of these technologies and personnel is the key to the success of Phase 0 clinical trial. This paper mainly introduces the benefit-risk assessment strategy, required technologies, application requirements, and case analysis of the new paradigm for novel drug development incorporating phase 0 clinical trial.

phase 0 clinical trial  /  drug benefit-risk assessment  /  drug development strategy  /  micro-concentration detection and analysis technology  /  case analysis  /  exploratory investigational new drug
Yan LIN, Qiao-hui LIANG, Zhi-xia JIANG, Jing CAI, Guang-ji WANG, Jin YANG. A new paradigm for novel drug development incorporating Phase 0 clinical trial[J]. Chinese Journal of Clinical Pharmacology, 2026 , 42 (4) : 565 -572 . DOI: 10.13699/j.cnki.1001-6821.2026.04.018
Year 2026 volume 42 Issue 4
PDF
156
33
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2026.04.018
  • Receive Date:2025-11-12
  • Online Date:2026-08-06
  • Published:2026-02-28
Article Data
Affiliations
History
  • Received:2025-11-12
Funding
Affiliations
    1a.School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
    1b.State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
    1c.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
    1d.School of Science, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
    1e.School of Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu Province, China
    2.Shanghai Guanhe Pharmaceutical Technology Co., Ltd., Shanghai 200433, China
    3.The Second Affiliated Hospital of Xinjiang Medical University, Urumqi 830028, Xinjiang Uyghur Autonomous Region, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2026.04.018
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT